← Back
$OKUR All transactions

OnKure Therapeutics, Inc.

▲ BUY
6 / 10

Conviction

$ Value

$500K

Shares

270,270

Price

$2

Filed

May 19

Why this score? (6/10)
  • Open market buy (+3)
  • Trade value >= $250K (+1)
  • 10%+ owner (+1)
  • Not a 10b5-1 plan (+1)

Insider

Name

ACORN BIOVENTURES, L.P.

Title

CIK

0001766853

Roles

10% Owner

Transaction Details

Transaction Date

2025-05-15

Code

P

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

1,709,944

Footnotes

Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. | Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Filing Info

Accession No.

0000950170-25-074459

Form Type

4

Issuer CIK

0001637715

ACORN BIOVENTURES, L.P.'s History

Date Ticker Type Value
2025-05-15 OKUR $500K
2025-05-15 OKUR $2.1M

Other Insiders at OKUR (90d)

Insider Bought Sold Last
Ratcliffe Liam 2026-03-31
Saccomano Nicholas A
President and CEO
$357 2026-04-01
Leverone Jason A.
Chief Financial Officer
$1K 2026-04-01
Agresta Samuel
Chief Medical Officer
2026-04-01
Hartley Dylan
Chief Scientific Officer
2026-04-01